Saturday 17 October 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.6% and free cash flow grew 67.0%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
0.62
0.02
−3.13%
Follow TPST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (931.14%) | (721.00%) | (203.63%) | (405.03%) |
+8 more TTM periods Free account |
|
| (237.25%) | (200.87%) | (89.91%) | (141.49%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,785.27% | 13,468.13% | (472.34%) | (685.44%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.36) | (2.41) | (6.46) | (7.52) | |
Free Cash Flow |
(20.73) | (26.38) | (26.82) | (33.39) | |
| Other line items | |||||
Cash ROIC |
6,665.59% | (1,004.26%) | (186.57%) | (240.95%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.51 | 0.61 | 1.02 | 0.93 | |
Depreciation/Fixed assets |
0.52 | 0.47 | 0.44 | 0.37 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.36) | (2.41) | (6.46) | (7.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates